SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2017, and provide a general business overview on Wednesday, February 28, 2018, at 4:30 p.m. ET (1:30 p.m. PT).
Conference Call Details
The live conference call on Wednesday, February 28, 2018, at 4:30 p.m. ET, can be accessed by phone by calling (844) 452-6828 from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 4893459. The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
[email protected]
Media Contact:
Laurie Masonson
W2O Group
[email protected]
